The Hidden Manufacturing Talent Crisis
The Hidden Manufacturing Talent Crisis In life sciences, manufacturing has quietly become one of the most consequential constraints on growth. Not because companies lack capital, assets, or demand—but because they lack people with the right operational “scar tissue” to scale complex products under GMP conditions. This is the hidden manufacturing talent crisis: the sector’s manufacturing […]
What VC-Backed Biotech Boards Expect from Leadership
In VC-backed biotech, boards are not simply governance bodies—they are active stakeholders underwriting scientific risk with time-bound capital. Their expectations of leadership are therefore different from those in large pharma and meaningfully more demanding than many first-time CEOs anticipate. Boards are betting on a company’s ability to convert uncertainty into value through credible plans, disciplined […]
Why Rare Disease Requires a Different Commercial Strategy
Commercial playbooks built for primary care or broad specialty indications routinely underperform in rare disease. Not because the fundamentals of commercialization change—but because the market mechanics do. Rare disease is defined by small, dispersed patient populations, diagnostic complexity, and high clinical and financial stakes. Success depends less on reach and repetition and more on precision: […]